Target intelligence / Profile preview

Salmonella Enteritidis O-polysaccharide antigen (SE OAg)

Target
SE OAg
Molecular classification
Polysaccharide, Bacterial surface antigen, Lipopolysaccharide component
01

Overview

The O-polysaccharide (O-antigen) of Salmonella Enteritidis is the distal, repeating carbohydrate component of the lipopolysaccharide (LPS) located on the bacterial outer membrane (NIH, 2024). It is composed of a trisaccharide backbone consisting of mannose, rhamnose, and galactose, with a unique alpha-3,6-tyvelose side chain that defines the O:9 serogroup specificity (NIH, 2024; ASM, 2026). This molecule plays a vital role in bacterial pathogenesis by protecting the organism from complement-mediated lysis and facilitating survival within host macrophages and the environment (ResearchGate, 2024; ASM, 2026). As a primary target of the host immune response, the O-antigen is the focus of various vaccine development efforts, including glycoconjugate vaccines and live attenuated strains (PLOS, 2024; Frontiers, 2024). These vaccines aim to elicit high-titer, functional antibodies that enhance bacterial clearance through opsonization and bactericidal activity (Scilit, 2024; NIH, 2024).

Other names
Salmonella Enteritidis O-antigenSomatic antigen 9O:9 antigenSalmonella Enteritidis OPSLipopolysaccharide O-side chain
02

Mechanism of action

Induction of serovar-specific antibodies (IgG, IgM) that promote opsonophagocytosis and complement-mediated killing of the bacteria.

03

Biological functions

Immune evasionComplement resistanceHost-pathogen interactionSerovar specificityEnvironmental persistence
04

Disease associations

SalmonellosisInvasive nontyphoidal salmonellosisGastroenteritisBacteremia
05

Safety considerations

Reactogenicity due to endotoxin activitySerotype replacementEnvironmental shedding of live vaccine strainsPotential for reduced immunogenicity without protein conjugation
06

Interacting drugs

COPS-flagellin conjugate vaccine

3 more in the full profile.

07

Biomarkers

Anti-OAg IgG titerAnti-OAg IgM titerSerum bactericidal activity (SBA)Opsonophagocytic activity (OPA)

Beyond the preview

Go deeper on Salmonella Enteritidis O-polysaccharide antigen (SE OAg).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Salmonella Enteritidis O-polysaccharide antigen (SE OAg).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call